SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alexza(ALXA)-No Pain! Big Gain!!!!!
ALXA 0.9350.0%Jun 21 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (11)7/29/2007 7:09:04 PM
From: tuck  Read Replies (1) of 26
 
"Our business model is based on an assumption of cost of goods for our devices of under $5 per unit at volume manufacturing, and we need to satisfy ourselves that we will be able to achieve a sales price in excess of $15 per unit to proceed with a development program. In all of our programs under development, we believe that we will be able to achieve these unit prices based on the advantages that our technology delivers: rapid onset, ease of use, consistent particle size, and consistent dose."

CEO King from the MF interview.

"The later, the better," is a dicey rule. Think CTIC and TELK, for examples of later being worse. Seems as though that wouldn't be a big help in migraine studies, but I'm no expert. Per that interview, the two timelines you give appear to be correct. I haven't priced popular migraine medications, but I bet Rick knows that stuff off of the top of his head.

I've bought a little SNUS, and am trying to get some ARQL. Also looking at SNMX. You still follow that one?

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext